Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Update

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 114,388 shares, a decrease of 71.6% from the August 31st total of 403,209 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average trading volume of 95,127 shares, the days-to-cover ratio is currently 1.2 days.

Kairos Pharma Trading Down 2.3%

KAPA stock traded down $0.04 during mid-day trading on Monday, hitting $1.68. 51,778 shares of the company were exchanged, compared to its average volume of 148,142. Kairos Pharma has a 1-year low of $1.51 and a 1-year high of $9.59. The stock has a market capitalization of $5.70 million, a PE ratio of -0.86 and a beta of 1.48. The business has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.99.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.42) EPS for the quarter. Equities research analysts expect that Kairos Pharma will post -2.59 earnings per share for the current year.

About Kairos Pharma

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on immuno-oncology, with an emphasis on addressing mechanisms that can cause tumors to resist existing treatments.

Kairos Pharma’s lead program, KPA-1102, is an investigational antibody designed to inhibit leukemia inhibitory factor (LIF), a signaling protein associated with tumor growth and immune suppression. The company is evaluating the potential use of this approach in combination with other cancer therapies, including immune checkpoint inhibitors.

The company is based in the United States and is focused primarily on advancing its drug candidates through clinical development and regulatory processes.